Xeina Drugs, since its inception, has been focused on bringing differentiated and specialized products across the emerging markets.
In this endeavor, we are pleased to inform that Xeina Drugs has been authorized to represent Celin Technologies OU to license their product for Critical Limb Ischemia (CLI) to emerging markets.
CLI is a disease arising from atherosclerosis of the extremities in the peripheral blood vessels and is characterized by narrowing and hardening of the arteries that supply the legs and feet. The narrowing of the arteries causes a decrease in blood flow. Symptoms include leg pain, numbness, cold legs or feet and muscle pain in the thighs, calves or feet.
Limb amputation is the only treatment option if other conventional treatments fail.
Diabetes, which is a growing concern in India and emerging markets, drives the inflammation and slowing blood flow and accelerates atherosclerosis, making patients vulnerable to CLI. Currently, emerging markets have over 160 million patients, which have been diagnosed with diabetes. India alone has over 70 million patients of diabetes.
Cellin has developed a proprietary cell therapy product from mesenchymal stem cells (MSC) in stem cell therapy regenerative treatment, which can be a potential treatment option for CLI and can prevent patients from undergoing amputation.